Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 71.4%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Diflunisal vs placebo

Health‐related quality of life (mental) · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low

Diflunisal vs placebo

Has died · people with TTR‐FAP

It is very uncertain whether diflunisal changes number of participants who died during the trial compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 0.46 [0.15, 1.41]
1 study · 130 participants
Very low

Diflunisal vs placebo

Withdrawals due to adverse events · people with TTR‐FAP

It is very uncertain whether diflunisal changes number of dropouts due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 2.06 [0.39, 10.87]
1 study · 130 participants
Very low

Diflunisal vs placebo

Number of participants experiencing at least one severe adverse event · people with TTR‐FAP

It is very uncertain whether diflunisal changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 0.77 [0.18, 3.32]
1 study · 130 participants
Very low

Diflunisal vs placebo

Disability due to FAP progression (expressed as the change in Kumamoto Score) Scale from: 0 (normal) to 102 (worst disease severity). · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Low

Diflunisal vs placebo

Severity of peripheral neuropathy (expressed as the change in NIS+7) Scale from: 0 (normal) to 270 (total impairment) · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Low

Diflunisal vs placebo

Physical quality of life · people with TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 130 participants
Very low